BTIG Research Issues Pessimistic Forecast for Humacyte (NASDAQ:HUMA) Stock Price

Humacyte (NASDAQ:HUMA) had its target price reduced by BTIG Research from $3.00 to $2.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s target price would indicate a potential upside of 74.67% from the company’s current price.

A number of other research analysts have also commented on the stock. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research note on Tuesday, April 28th. Wall Street Zen lowered shares of Humacyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, April 11th. Benchmark decreased their price target on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $7.57.

Humacyte Stock Performance

Shares of Humacyte stock traded up $0.24 during trading on Wednesday, hitting $1.15. 19,093,454 shares of the stock were exchanged, compared to its average volume of 6,415,261. The stock has a market capitalization of $254.21 million, a price-to-earnings ratio of -5.73 and a beta of 2.31. The company has a fifty day moving average price of $0.86 and a 200-day moving average price of $1.07. Humacyte has a 1-year low of $0.55 and a 1-year high of $2.93. The company has a current ratio of 3.69, a quick ratio of 2.95 and a debt-to-equity ratio of 20.08.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Humacyte had a negative net margin of 1,998.87% and a negative return on equity of 990.48%. As a group, equities analysts predict that Humacyte will post -0.39 EPS for the current fiscal year.

Institutional Trading of Humacyte

Institutional investors and hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Humacyte by 841.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 70,414 shares of the company’s stock worth $68,000 after acquiring an additional 62,931 shares during the period. Aristides Capital LLC bought a new stake in shares of Humacyte during the 4th quarter worth approximately $156,000. Fisher Asset Management LLC bought a new position in Humacyte in the 4th quarter valued at approximately $47,000. UBS Group AG lifted its stake in Humacyte by 48.8% in the 4th quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock valued at $2,862,000 after purchasing an additional 976,275 shares during the last quarter. Finally, R Squared Ltd bought a new position in Humacyte in the 4th quarter valued at approximately $25,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.